AstraZeneca enters the BACE inhibitor Phase III stakes
This article was originally published in Scrip
On the back of its recent deal with Lilly, AstraZeneca has moved its BACE inhibitor AZD3293 into Phase III testing in mild Alzheimer's disease and mild cognitive impairment, making it the second late-stage drug still in contention in this novel, but very high-risk drug class. The pipeline advance also puts the firm well on track to deliver on its Phase III pipeline promises for this year.
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.